Patent intelligence · US
US 9200028
Steroids having increased water solubility and resistance against metabolism and methods for their production
Steroids having increased water solubility and resistance against metabolism and methods for their production
Patent details — US 9200028
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 1, 2015
- Expiration
- Nov 26, 2035
- Applicant
- Umecrine Cognition AB
- Claims
- 2
- CPC classes
- A61P, A61P15/00, A61P19/00, A61P19/08
Quick answer
US 9200028 (Steroids having increased water solubility and resistance against metabolism and methods for their production) is held by Umecrine Cognition AB. Status: granted. Granted Dec 1, 2015. Expires Nov 26, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Umecrine Cognition AB
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P15/00, A61P19/00, A61P19/08, A61P21/00, A61P25/00
More from Umecrine Cognition AB
Related pharmaceutical patents in our USPTO index.
-
US 12208167
Coated tablets for pH-dependent release of benzgalantamine
granted -
US 12157743
Solid forms of Alpha-1062 gluconate
granted -
US 11795176
Solid forms of Alpha-1062 gluconate
granted -
US 11123351
Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
granted -
US 10603326
Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime
granted -
US 10351589
3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders
granted -
US 10342804
Steroid compound for use in the treatment of hepatic encephalopathy
granted -
US 10278977
Methods for treating hypersomnolence
granted
Frequently asked questions
What is US patent 9200028?
US 9200028 (Steroids having increased water solubility and resistance against metabolism and methods for their production) is held by Umecrine Cognition AB. Status: granted. Granted Dec 1, 2015. Expires Nov 26, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9200028?
Umecrine Cognition AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 9200028 expire?
Our index shows an expiration date of Nov 26, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.